2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human, Adult, Animal Model
PAPER

4997 Integrated multi-omics reveals a non-canonical role for CDK1-dependent protein synthesis in AML survival

Daniela Ortiz Chavez, BS, BA, Kate Matlin2, Marco De Dominici, PhD3, Usman Hyder, PhD4, Maxwell McCabe, PhD5, Michael Kaufman, PhD6, Neelanjan Mukherjee, PhD7, Craig Jordan, PhD8, Mark Gregory, PhD9, James Degregori, PhD10
1 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
2 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
3 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
4 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
5 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
6 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
7 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
8 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
9 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
10 University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Background
FLT3 inhibitors have improved outcomes for patients with FLT3-mutated acute myeloid leukemia (AML). However, patients ultimately relapse due to the inability to effectively eliminate AML cells in the bone marrow (BM). We previously showed how BM stromal cell mediated mTORC1 activity maintains AML survival despite FLT3 inhibition by promoting protein translation. Still, pharmacologic mTORC1 inhibition alone produces only modest reductions in protein synthesis and AML cell survival, indicating that mTORC1-independent translational mechanisms contribute to AML survival. To define these mechanisms, we integrated functional studies with transcriptomic and nascent proteomic profiling to identify translation programs that sustain AML survival.

Methods
Protein synthesis was quantified by O-propargyl-puromycin (OPP) incorporation following pharmacologic and genetic perturbation of candidate kinases across AML cell lines harboring either FLT3-ITD or wild-type FLT3. Cell viability and cell cycle progression were assessed by flow cytometry. Pulse SILAC-based nascent proteomics was integrated with bulk RNA sequencing to distinguish translational from transcriptional regulation through translational efficiency (TE) analyses. Differential alternative splicing was evaluated using rMATS.

Results
Consistent with our previous observations, mTORC1 inhibition effectively suppressed canonical mTORC1 signaling yet produced only minor reductions in protein synthesis, proliferation and viability, indicating that AML cells can maintain translation through mTORC1-independent mechanisms. A focused kinase inhibitor screen identified CDK1 as the most critical regulator of mTORC1-independent protein synthesis. Pharmacologic and genetic inhibition of CDK1 consistently and potently reduced protein synthesis across multiple AML cell lines. Even transient CDK1 inhibition resulted in complete AML cell killing after inhibitor washout. Importantly, CDK1 inhibition reduced protein synthesis at concentrations producing minimal cell-cycle perturbation, while higher concentrations induced substantially greater cell-cycle arrest without proportionally greater suppression of translation. Furthermore, protein synthesis declined within three hours of treatment, preceding detectable cell-cycle arrest, and translational inhibition was evident throughout the cell cycle, supporting a translation-regulatory role for CDK1 independent of its canonical cell-cycle function.

To define the molecular basis of this translation-specific role, we integrated nascent proteomic and transcriptomic datasets to distinguish translational from transcriptional regulation. Through TE analyses, CDK1 inhibition had a markedly greater impact on the nascent proteome than mTORC1 inhibition, with each kinase regulating the synthesis of largely distinct sets of proteins. These integrated analyses showed that CDK1 inhibition preferentially disrupted pathways involved in RNA processing, protein synthesis, and protein homeostasis, whereas mTORC1 inhibition produced comparatively modest pathway-level changes. In parallel, differential splicing analyses demonstrated widespread alternative splicing following CDK1 inhibition, particularly among genes encoding spliceosomal and RNA-processing factors, while mTORC1 inhibition induced comparatively few splicing alterations. Together, these findings identify CDK1 as a key regulator of protein synthesis in AML beyond its canonical role in cell-cycle progression, revealing previously unrecognized roles in both translational and post-transcriptional regulation.

Conclusions
Integrated transcriptomic and nascent proteomic profiling demonstrates that AML cells sustain protein synthesis through distinct mTORC1- and CDK1-regulated translational programs. Beyond its established role in cell-cycle progression, CDK1 emerges as a key regulator of mTORC1-independent translation and post-transcriptional gene regulation, supporting leukemic cell survival. These findings support the hypothesis that perturbation of the translational machinery limits the production of proteins required for leukemic adaptation and survival, identifying adaptive translation as a central mechanism supporting AML persistence.

Daniela Ortiz Chavez, BS, BA: No relevant conflicts of interest to declare.